INCY Incyte Genomics Inc SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Best Biotech Stocks 2026 →

Incyte Genomics (INCY) Stock: Buy, Sell, or Hold?

$122.27
+1.97 (+1.64%) ▲
5d: -0.47% 30d: +12.57% 90d: +1.45%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (47%)
Quality Score
52/100
Position
EXTENDED
30-Day Fair Range
$112.25 – $119.13
Position: EXTENDED
Forward P/E & Valuation
14.2x FAIR
vs 12.5x historical avg
Wall Street Target
$131.50
+7.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$111.01 / $123.96
Trend: Strong Uptrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: INCY shows conflicting indicators. Wait for confirmation before entering.
Smart Money Distribution

Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →

Signal fired Oct 29, 2026 at $116.80 · last confirmed Nov 6, 2026

Strength: 7.6/10

Get Alerted When INCY Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$210.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$130.57
6.4% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.5x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: INCY is currently trading at $122.27, which is considered extended relative to its 30-day fair value range of $112.25 to $119.13. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.2) compared to its historical average (12.5). At these levels, the market is pricing in 4.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, INCY is in a strong uptrend. The price is approaching resistance at $123.96. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED
Historical Trading Range $112.25 - $119.13
Company Quality Score 52/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 47.1%

Trading Range & Key Levels

30-Day Trading Range $112.25 - $119.13
Current vs Trading Range EXTENDED
Support Level $111.01
Resistance Level $123.96
Current Trend Strong Uptrend
Technical data as of Nov 11, 2026

Protect Your Profits

Holding INCY? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

Quantitative Signal Breakdown

  • BEARISH: Price extended above range
  • NEUTRAL: Mixed technical signals (44/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($131.50)
  • NEUTRAL: Market pricing in 4.3% annual earnings growth - fairly valued
  • WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) 14.15
Wall Street Target $131.50 (+7.5%)
Revenue Growth (YoY) 14.0%
Earnings Growth (YoY) 37.7%
Profit Margin 6.7%
Valuation Premium vs History +4.3% premium
PE vs Historical 14.2 vs 12.5 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +4.3% (market-implied from PE analysis)
1-Year Target $127.53 (+4%)
2-Year Target $133.01 (+9%)
3-Year Target $138.73 (+14%)
3-Yr Target (if PE normalizes) (PE: 14→13) PE COMPRESSION $122.52 (+0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 19.9, Growth: 149.7%) $579.04 (+374%)
Base: (SPY PE: 14.2, Growth: 149.7%) $412.66 (+238%)
Bear: (PE: 12.0, Growth: 149.7%) $350.76 (+187%)
📈 Valuation based on Current Earnings
Forward PE: 13.68 | Forward EPS (Implied): $8.94
Bull Case $147.64 (+21%)
Analyst growth 15.0%, PE expands to 14.4
Base Case $122.27 (0%)
Market implied 0.0%, PE stable at 13.7
Bear Case $93.54 (-24%)
Severe decline -15.0%, PE contracts to 12.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share INCY Analysis

Share this live INCY analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

Reddit StockTwits X / Twitter
bloggers & journalists: you are free to use our charts with attribution.

Reddit & Retail Trader Sentiment (INCY)

Bullish 2 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 31, 2026
Daily AI digest
AI Retail Discussion Summary: Top Wall Street analysts upgraded Rivian and Incyte, while downgraded Reddit in their research calls.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams. View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 5:42 AM ET
Data refreshes hourly during market hours. Next update: 6:42 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
See Full Scanner Results »
Technical Signals Check

Is INCY showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for INCY.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
DNLI
Denali Therapeutics Inc 		STRONG BUY
20 analysts 		$36 49 HOLD
WVE
Wave Life Sciences Ltd 		STRONG BUY
21 analysts 		$17 34 SELL
SRRK
Scholar Rock Holding Corp 		STRONG BUY
18 analysts 		$70 32 SELL
PALI
Palisade Bio Inc 		STRONG BUY
10 analysts 		$10 62 BUY
ZYME
Zymeworks Inc. Common St… 		STRONG BUY
14 analysts 		$42 42 HOLD
DNLI Denali Therapeuti…
49 HOLD
WVE Wave Life Science…
34 SELL
SRRK Scholar Rock Hold…
32 SELL
PALI Palisade Bio Inc
62 BUY
ZYME Zymeworks Inc. Co…
42 HOLD

Advanced INCY Option Strategies

Professional options setups generated by AI based on today's INCY price and gamma walls.

Iron Condor Bull Call Bear Put Collar

Explore More Analysis & Live Quant Tools

Part A: Deep-Dive INCY Research Pages
INCY Technical Chart INCY Price Prediction INCY Intrinsic Value DCF INCY Earnings Date INCY Investment Advisor INCY Fair Price Analyzer INCY Options Chain INCY Options Advisor INCY Options Analysis INCY Competitors
Part B: Tradestie Flagship Market Scanners
Today's Best Signals (INCY) Sector Rotation Monitor AI Supply Chain Money Flow Gamma Squeeze (GEX) Scanner Undervalued Stocks Scanner Insider Cluster Buying Reddit & WSB Sentiment Tracker Backtested Stock Scanner
Compare INCY with Peers
INCY vs BMRN
Which one to buy?
INCY vs VRTX
Which one to buy?
INCY vs REGN
Which one to buy?
INCY vs EXEL
Which one to buy?
INCY vs ALNY
Which one to buy?
ONC vs INCY
Winner: ONC
INCY vs IQV
CRL vs INCY
INCY vs MEDP
BNTX vs INCY
INCY vs ROIV
Winner: INCY
INSM vs INCY
SMMT vs INCY
HALO vs INCY
Winner: HALO
GERN vs INCY
Create New Comparison View All Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals